Uni-Bio Science Group

Uni-Bio Science Group EBIT

The EBIT of Uni-Bio Science Group (690.HK) as of Oct 23, 2026 is 89.43 M HKD. In the previous year, EBIT was 75.94 M HKD — a change of 17.76% (higher).

EBIT

89.43 MHKD

YoY

17.76%

Last updated:

In 2024, Uni-Bio Science Group's EBIT was 89.43 M HKD, a 17.76% increase from the 75.94 M HKD EBIT recorded in the previous year.

The Uni-Bio Science Group EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2017
-79.81 M HKD
Jan 1, 2018
-118.64 M HKD
Jan 1, 2019
-59.13 M HKD
Jan 1, 2020
-38.87 M HKD
Jan 1, 2021
-2.12 M HKD
Jan 1, 2022
45.21 M HKD
Jan 1, 2023
75.94 M HKD
Jan 1, 2024
89.43 M HKD
The Uni-Bio Science Group EBIT history
YEAREBITYoY
89.43 MHKD+17.76%
75.94 MHKD+67.98%
45.21 MHKD-2,237.54%
-2.12 MHKD-94.56%
-38.87 MHKD-34.27%
-59.13 MHKD-50.16%
-118.64 MHKD+48.65%
-79.81 MHKD+43.22%
-55.73 MHKD-3.44%
-57.71 MHKD+27.13%
-45.40 MHKD-58.92%
-110.50 MHKD+77.65%
-62.20 MHKD-19.53%
-77.30 MHKD+6.92%
-72.30 MHKD-49.93%
-144.40 MHKD-39.38%
-238.20 MHKD-170.98%
335.60 MHKD+157.96%
130.10 MHKD-2,165.08%
-6.30 MHKD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Uni-Bio Science Group Revenue

Uni-Bio Science Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
156.48 M HKD
-79.81 M HKD
-279.31 M HKD
Jan 1, 2018
135.26 M HKD
-118.64 M HKD
-138.57 M HKD
Jan 1, 2019
209.45 M HKD
-59.13 M HKD
2.46 M HKD
Jan 1, 2020
208.78 M HKD
-38.87 M HKD
-71.32 M HKD
Jan 1, 2021
353.41 M HKD
-2.12 M HKD
-19.59 M HKD
Jan 1, 2022
440.32 M HKD
45.21 M HKD
38.51 M HKD
Jan 1, 2023
484.72 M HKD
75.94 M HKD
70.88 M HKD
Jan 1, 2024
552.98 M HKD
89.43 M HKD
82.77 M HKD

Uni-Bio Science Group Margins

Uni-Bio Science Group stock margins

The Uni-Bio Science Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Uni-Bio Science Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Uni-Bio Science Group.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
85.40 %
-51.00 %
-178.50 %
Jan 1, 2018
86.95 %
-87.72 %
-102.45 %
Jan 1, 2019
86.66 %
-28.23 %
1.17 %
Jan 1, 2020
86.74 %
-18.62 %
-34.16 %
Jan 1, 2021
78.38 %
-0.60 %
-5.54 %
Jan 1, 2022
76.06 %
10.27 %
8.75 %
Jan 1, 2023
81.04 %
15.67 %
14.62 %
Jan 1, 2024
83.38 %
16.17 %
14.97 %

Uni-Bio Science Group Stock analysis

What does Uni-Bio Science Group do? Uni-Bio Science Group Ltd. generates revenue through four segments: in-house chemical pharmaceutical products like Pinapu, in-house biological pharmaceutical products such as GeneTime and GeneSoft, in-house biological pipeline products including Uni-E4 and Uni-PTH, and third-party pharmaceutical products. The company manufactures and sells its own chemical and biological products while also distributing third-party pharmaceuticals. Its primary customers are healthcare providers and pharmaceutical distributors purchasing these branded products. The firm's revenue streams are directly tied to the production and distribution of these specific branded pharmaceuticals across its operational segments. The in-house chemical pharmaceutical segment focuses on products like Pinapu, which is sold to medical institutions and pharmacies. The biological pharmaceutical segment markets GeneTime and GeneSoft for specialized treatments, targeting hospitals and clinics. The biological pipeline segment develops Uni-E4 and Uni-PTH for future commercialization, while third-party pharmaceutical sales involve distributing external brands without direct manufacturing. These segments collectively drive the company's revenue through product sales and distribution agreements. Uni-Bio Science Group's business model relies on both direct manufacturing of its branded pharmaceuticals and third-party product distribution. The company's revenue comes from the sale of Pinapu, GeneTime, GeneSoft, Uni-E4, and Uni-PTH as well as third-party pharmaceuticals. Healthcare institutions and pharmaceutical distributors are the key buyers of these products across all segments, with the in-house products forming the core of the company's revenue generation strategy. Uni-Bio Science Group is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Uni-Bio Science Group's EBIT

Uni-Bio Science Group's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Uni-Bio Science Group's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Uni-Bio Science Group's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Uni-Bio Science Group’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Uni-Bio Science Group stock

EBIT of Uni-Bio Science Group is 89.43 M HKD in 2024.

EBIT of Uni-Bio Science Group changed from 75.94 M HKD to 89.43 M HKD, representing a 17.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Uni-Bio Science Group since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's HKD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Uni-Bio Science Group historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Uni-Bio Science Group

All Key Metrics — Uni-Bio Science Group